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Abstract
The impressive benefits related to the use of tight glucose control
by intensive insulin therapy have not been reproduced until now in
multicenter large-scale prospective randomized trials. Although the
reasons for these failures are not entirely clear, we suggest the use
of a stepwise approach – Safe, Effective Glucose Control – that
will essentially target an intermediate blood glucose level. As com-
pared with genuine tight glucose control, Safe, Effective Glucose
Control – already used in many intensive care units worldwide – is
intended to decrease the rate of hypoglycemia and the workload,
while reducing the adverse effects of severe hyperglycemia.
In 2001, following in the path of the glycemic pioneers [1-3],
the Leuven 1 investigators published their landmark study of
intensive insulin therapy in a population of surgical intensive
care unit (ICU) patients, targeting 80 to 110 mg/dl in the
interventional arm [4]. This prospective, controlled randomized
trial spurred clinicians in ICUs around the world to adopt tight
glycemic control (TGC) [5]. Confirmation of the mortality
benefit of TGC in a mixed medical–surgical ICU setting was
seen in the nonrandomized Stamford study published nearly
3 years later [6,7]. An additional 2 years elapsed until the
publication of the Leuven II study, performed in a medical ICU,
which demonstrated reduced mortality in the predefined
population of patients staying in the ICU for at least 3 days but
not in the entire population [8]. Two subsequent multicenter
studies – GLUCONTROL and VISEP – were terminated
prematurely, mainly because of the occurrence of severe hypo-
glycemia without concurrent improvement in survival [9,10].
Why were the benefits of TGC apparent in the earlier studies
not confirmed in the more recently published work?
TGC demands a complex application of monitoring and
dynamic treatment throughout the course of the patient’s ICU
stay; deficiencies in any number of institutional factors may
doom the intervention to failure. Protocol-driven care is
central to TGC, with frequent assessment of glycemic levels
and responding adjustments in the administered treatment.
The experience and skill of the nursing staff in the use of
protocols will materially affect the probability that the
treatment goals of the protocol are achieved. Moreover, the
structural and organizational characteristics of the ICU may
have a strong impact, especially in view of the high work
burden imposed by TGC – estimated to consume up to
2 hours out of a 24-hour working day for the ICU nurse [11,12].
Appropriate data outcome tools greatly increase the chance
that TGC will be practiced successfully. Glycemic reporting
tools allow clinicians to know whether glycemic targets are
being reached and, importantly, whether there is a significant
rate of treatment-associated hypoglycemia. Ideally an ICU
should also have an outcomes reporting tool – the ability to
provide information such as severity-adjusted mortality and
length of stay, complications and resource utilization. Positive
feedback imparts a strong incentive to continue the effort
needed to maintain effective implementation of TGC [13,14].
One important difference between the early and later trials of
TGC is the rate of treatment-associated severe hypo-
glycemia, defined as <40 mg/dl, found recently to confer
increased risk of mortality in a large cohort of mixed
medical–surgical ICU patients [15]. The Leuven I study
reported an increase in the number of patients with severe
hypoglycemia from 0.8% to 5.1%, with no associated
adverse consequences [4]. There was no increase in severe
hypoglycemia in the Stamford study [6]. In contrast, the
percentages of patients in the corresponding groups of the
Leuven II study were 3.1% and 18.7% (25.1% among
patients in the ICU for longer than 5 days) [8]. In this study
the occurrence of severe hypoglycemia was independently
associated with mortality on multivariable analysis and
resulted in an attenuation of the survival benefit of TGC [8].
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Similarly, the percentage of patients sustaining severe hypo-
glycemia among patients in the interventional arm versus the
control arm of the GLUCONTROL trial was 2.7% versus
9.8% [9]; the corresponding rates in the VISEP trial were
4.1% and 17.0% [10]. It is possible that differences in
monitoring technology and testing frequency may explain
some of the differences in the rates of severe hypoglycemia
when comparing the Leuven 1 study, which exclusively used
arterial blood from indwelling arterial catheters, with the later
studies. A growing literature has described the limitations of
capillary glucose measurement in the critically ill patient,
especially in the lower ranges targeted by these trials [16,17].
It is likely that an additional factor – glycemic variability – has
played a role in explaining the divergent outcomes of these
different interventional trials [18,19]. A new evaluation of
glycemic variability, defined as the standard deviation of the
mean glucose level during the ICU stay, suggests that
glycemic variability may be an even more important predictor
of mortality in the critically ill patient than is the mean glucose
level [20]. It is intriguing to note that while the mean
(standard deviation) morning glucose levels of the control and
interventional arms of the Leuven I study were 153 (33) mg/dl
versus 103 (19) mg/dl [4], the corresponding results for the
Leuven II study were 153 (31) mg/dl versus 111 (29) mg/dl
[8]. Glycemic control improved in the second study but,
perhaps, glycemic variability was unchanged.
We are forced, ultimately, to conclude that the Leuven I study
may have set the bar too high: TGC, with a glycemic target of
80 to 110 mg/dl is, simply, too tight to practice safely and
effectively. If TGC cannot be implemented safely and
effectively in a research setting leading to a published inter-
ventional trial, then it probably cannot be implemented safely
and effectively by most ICU teams.
Instead of TGC, we propose a stepwise approach defining a
new standard – Safe, Effective Glycemic Control (SEGC)
[21,22]. SEGC involves, first, adoption of a safe glycemic
target appropriate to the skills, experience and available tools
of the ICU that does not result in a significant increase in the
rate of hypoglycemia. A glycemic target of 80 to 150 mg/dl is
not unreasonable for an ICU to choose initially; implemen-
tation can subsequently lead to downward revision of the
glycemic goal. Effective implementation of TGC involves
successful attainment of glycemic goals with minimum
variability. The use of appropriate data monitoring tools, for
both glycemic results and relevant clinical outcomes, is
essential for SEGC. Finally, sensible utilization of existing
monitoring technologies is mandatory for SEGC.
Preliminary clinical evaluations of the accuracy of continuous
or near-continuous glucose monitors have been published
recently [23-25]. These devices offer the promise of a
reduction in severe hypoglycemia, glycemic variability and the
nursing work burden, and will probably become a corner-
stone of SEGC. The goals of the SEGC mandate team
collaboration are to create and apply glycemic protocols, and
the appropriate use of all of the data and monitoring tools that
we currently have in our armamentarium, as well as rapid
employment of new tools as they are developed. Our patients
deserve no less.
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